Only after consulting your physician
Some studies report trends towards neuroprotectivity with associated reductions in neurodegenerative conditions like Alzheimers and Parkinsons noted in some of these medications
We are incredibly excited to see these results and they will have deep implications well beyond US populations
"GI AEs typically occur during initiation and uptitration, appearing as transient, mild-to-moderate symptoms." Laura Schalliol, PharmD, BCACP, BCGP, Professor of Pharmacy Practice In fact, 94% of adverse events reported in major clinical trials were mild or moderate in severity
A more complete plateau, when the scale essentially stops moving, typically arrives between 12 and 18 months for most patients, though a small proportion will continue losing weight for up to two years
Collectively, these two studies elucidate the role of EAT in AF from two distinct dimensions: EAT heterogeneity (pathological complexity) and overall mass (early quantitative changes)